Recombinant LRP 5/6 抗体
适用: 人, 小鼠
FACS
宿主: Human
Monoclonal
Heldy-1-4
unconjugated
Recombinant Antibody
-
- 抗原
- LRP 5/6
- 抗体类型
- Recombinant Antibody
- 适用
- 人, 小鼠
- 宿主
-
Human
- 克隆类型
- 单克隆
- 应用范围
- Flow Cytometry (FACS)
- 特异性
- Recognizes human and mouse LRP5 & LRP6.
- 交叉反应
- 人, 小鼠
- 纯度
- >95 % (SDS-PAGE)
- 免疫原
- Recombinant mouse LRP6.
- 克隆位点
- Heldy-1-4
- 亚型
- IgG2
-
- 说明
-
anti-LRP5/6 (human), mAb (rec.) (Heldy-1-4) is composed of human variable regions (VH and VL) (lambda-chain) of immunoglobulin fused to the human lgG2 Fc domain.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- Lot specific
- 缓冲液
- In PBS containing 10 % glycerol.
- 储存条件
- 4 °C,-20 °C
- 储存方法
-
Short Term Storage: +4°C
Long Term Storage: -20°C
Stable for at least 1 year after receipt when stored at -20°C. - 有效期
- 12 months
-
- 抗原
- LRP 5/6
- 别名
- LRP5/6
- 背景
- Wnt/beta-catenin signaling acts as a regulator of tissue development and homeostasis. Wnt ligands bind to a member of the Frizzled family of seven-transmembrane proteins and to either highly homologous low-density lipoprotein related receptors 5 (LRP5) or LRP6. Low-density lipoprotein receptor-related protein 6 (LRP6) is a member of the low-density lipoprotein receptor (LDLR) family. LRP5 and LRP6 are expressed in most human tissues and is composed of three distinctive cell-surface protein domains, including (1) LDL receptor (LDLR) type A repeats, (2) an epidermal growth factor (EGF)-like domain, and (3) a YWTD (Tyr-Trp-Thr-Asp)-type beta propeller domain. LRP6 is inhibited by the Dickkopf protein Dkk1 bound to their partners Kremen. Sclerotin also acts as an inhibitor of LRP5/6 through LRP4. LRP6 is involved in cell differentiation, proliferation and migration during embryonic development and in the pathogenesis of different cancer types. LRP6 plays a major role in metabolic regulation, specifically in the nutrient-sensing pathway. Patients carrying an LRP6 mutation exhibit high serum LDL cholesterol and triglycerides, hypertension, high fasting blood glucose levels, a prevalence of diabetes and low bone density. LRP6 mutations have also been associated with diseases such as Alzheimer's and degenerative joint diseases. LRP5, low-density-lipoprotein-receptor-related protein 5, is a determinant for bone mineral density and plays a role in osteoporosis. LRP5 is aso involved in vitreoretinopathy.
-
You are here:
